CVS Health Corporation’s Stock Price Drops to $67.46, Reflecting a 2.87% Decline: Time to Buy?

CVS Health Corporation (CVS)

67.46 USD -1.99 (-2.87%) Volume: 14.3M

CVS Health Corporation’s stock price stands at 67.46 USD, witnessing a trading session dip of -2.87%, despite a remarkable YTD growth of +50.28%. With a robust trading volume of 14.3M, CVS continues to be a key player in the health care sector, making its stock performance a focal point for investors.

Latest developments on CVS Health Corporation

Today, CVS Health Corp stock price movements were influenced by a series of key events leading up to this point. The company raised its profit forecast and announced plans to exit the Obamacare market, signaling a successful turnaround. CVS’ Aetna subsidiary will no longer offer Affordable Care Act health plans, boosting access to the weight loss drug Wegovy. The company also reported strong Q1 2025 results, with a focus on Medicare business growth. CVS Caremark placed Wegovy as the preferred GLP-1 for weight loss, dropping Lilly’s Zepbound in favor of Novo. These strategic decisions have led to a surge in stock price, hitting a 52-week high at $72.37. CVS Health Corp remains optimistic about its future outlook, raising its annual profit forecast as the turnaround gathers steam.

CVS Health Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have published two reports on Cvs Health Corp with differing sentiments. The first report, titled “CVS Health: $97.7 Billion Revenue and a New CEO – Can It Overcome Industry Challenges?”, leans bullish. It highlights the company’s significant turnaround following better-than-expected quarterly earnings, leading to a 14.8% rise in stock price. The second report, from Value Investors Club, takes a bearish stance on CVS, suggesting a potential 30%+ downside for the company due to declining performance in its Pharmacy & Consumer Wellness operations.

In another report by Baptista Research, titled “CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers,” the analysts present a more positive outlook on the company. Despite challenges indicated in the adjusted earnings per share, the report emphasizes CVS Health’s revenue increase of 6% to approximately $95.4 billion. With a focus on expansion and optimization of health services, the company aims to drive growth and overcome industry obstacles under the leadership of a new CEO.

A look at CVS Health Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CVS Health Corp seems to have a positive long-term outlook. The company scored highly in areas such as dividend and momentum, indicating strong performance in these aspects. With a focus on pharmacy benefit management services, retail pharmacy, and disease management programs, CVS Health Corp is well-positioned to continue its growth and resilience in the healthcare industry.

While the company scored slightly lower in areas such as growth and resilience, overall, CVS Health Corp’s Smart Scores suggest a favorable outlook. With a strong presence in the U.S. and Puerto Rico, offering a range of healthcare services, CVS Health Corp is likely to remain a key player in the industry for the foreseeable future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma